Innovation Hub

Sponsored in part by Varian Medical Systems and ViewRay Inc.

The Innovation Hub, a dedicated space within the virtual platform, will highlight new technologies, digital health innovation and informatics, artificial intelligence, entrepreneurship and more. This space will be used by attendees and industry representatives for interactive idea sharing, networking, imaginative business solutions and brainstorming sessions that will transform the industry.

In addition to the popular Industry-Expert Theaters and Industry Satellite Symposia, we have added Main Stage Presentations and 15-minute Lunchtime Product Demonstrations from featured exhibitors. New for this year, the Main Stage will host CEOs and CMOs of technology companies, designers, startups, key opinion leaders and business strategists. Additionally, attendees can get the latest information from exhibitors on their products during our 15-minute Lunchtime Product Demonstrations.

Main Stage Presentations

Sunday, October 25

4:30 p.m. - 4:50 p.m. | Startup Company: TibaRay
Presentation Title: FLASH RT and the development of PHASER, a medical linac platform for its clinical translation
Panelist: Billy W. Loo, Jr., MD, PhD, Cofounder & Board Member, TibaRay and Professor of Radiation Oncology, Stanford University School of Medicine


Monday, October 26

9:45 a.m. - 10:05 a.m. | Startup Company: Leo Cancer Care
Presentation Title: The case for upright Radiation Therapy - The topic of this presentation will be a broad look at the potential benefits that come from positioning patients in the upright
Panelists: Thomas "Rock" Mackie, PhD - Asto CT Inc. 
Niek Schreuder, MSc, DABR - Leo Cancer Care Ltd.

10:10 a.m. - 10:30 a.m. | Startup Company: Cybrexa
Session Title: Breaking Through to Synergy: The Potential of DDR Inhibitors in Combination with Radiotherapy
Panelists: Ranjit Bindra, MD, PhD, Yale University 
Peter Glazer, MD, PhD, Yale University

10:30 a.m. - 11:30 a.m. | Main Stage Presentation: ViewRay Inc.

11:30 a.m. - 11:50 a.m. | Startup Company: Concure Oncology
Session Title: One and done - Post pathology radiotherapy for early-stage breast cancer
Panelist: Alvaro Martinez, MD, Michigan Healthcare Professionals/Genesis Care

12:00 p.m. - 12:20 p.m. | Startup Company: bridge7
Session Title: Machine learning-based quality assurance for radiation oncology
Panelists: Meir Dick, bridge7 Oncology
Robert Fenwick, bridge7 Oncology
Chris McIntosh, University Health Network, University of Toronto 
Tom Purdie, PhD, University Health Network, University of Toronto

12:30 p.m. - 1:00 p.m. | Main Stage Presentation: Elekta

3:45 p.m. - 4:05 p.m. | Starup Company: Oncora Medical
Session Title: Deploying Machine Learning to the Cancer Clinic
Panelists: William Lindsay, CEO & Co-founder, Oncora Medical
Grace Smith, MD, Radiation Oncologist, MD Anderson Cancer Center


Tuesday, October 27

10:15 a.m. - 10:25 a.m. | Startup Company: Supportive Therapeutics
Session Title: ST-617 for the attenuation of Oral Mucositis in patients receiving chemoradiation for Head&Neckcancer today – a novel mechanistically targeted approach to prevention.
Speakers: Paul Song, Radiation Oncologist, Cedars-Sinai Medical Center Los Angeles, CA, USA
Daniel Osei-Fofie, Clinical and Radiation Oncologist, Kimberley Hospital Kimberley, South Africa
Stephen Sonis, Surgeon Primary Endpoint Solutions Waltham, MA and the Dana-Farber Cancer Institute Boston, MA, USA

10:30 a.m. - 10:50 a.m. | Startup Company: HPEC
Session Title: Restoring Privacy, Security and Trust to the Practice of Medicine
Speaker: Leah Houston, MD, Emergency Physician, CEO and Founder of HPEC

12:00 p.m. - 12:30 p.m. | Main Stage Presentation: Novocure
Session Title: Integrating Tumor Treating Fields (TTFields) into radiation practices: An overview TTFields dosimetry and treatment planning and the potential combination with radiation therapy.
Speakers: Wenyin Shi, MD, PhD, Thomas Jefferson University
Matthew Ballo, MD, FACR, West Clinic Cancer Center

2:00 p.m. - 3:00 p.m. | Main Stage Presentation
Session Title: Funding
Moderator: Sameer Keoloe, MD, FASTRO, MD Anderson Cancer Center
Speakers: Anatha V. Santhanam, PhD, MBA, Mayo Clinic Health System Rafael Torres, Varian Medical Systems

4:15 p.m. - 4:45 p.m. | Startup Company: TheraPanacea
Session Title: AI in radiology, "Reinventing cancer care through powerful AI "
Panelists: Prof. Nikos Paragyios, Founder and CEO of TheraPanacea
Vincent Gregoire, Chair of the Radiation Oncology Department Centre Léon Bérard
Eric Deutsch, Head of the Radiotherapy Department at the Institute Gustave Roussy
Thais Roque, Research and Clinical Partnerships Manager at TheraPanacea


Wednesday, October 28

12:00 p.m. - 1:00 p.m. | Main Stage Presentation
Session Title: Early Startup Experience
Moderators: David Jaffray, PhD, MD Anderson Cancer Center
Steven Frank, MD, MD Anderson Cancer Center,
Speakers: William R. Noyes, MD, Cancer Center of North Dakota
Thomas Rock Mackie, PhD, Morgridge Institute for Research
John R. Adler, MD, Stanford University

2:00 p.m. - 3:00 p.m. | Main Stage Presentation
Session Title: Early Interactions with FDA: The Pre-submission Program 
Moderator: Shilpen Patel, MD, FASTRO, Sutter Health
Panelists: John Nicholas Grimes, PhD, Vanderbelt University
Nancy Wersto, Food and Drug Administration

3:45 p.m. - 4:45 p.m. | Main Stage Presentation: Varian Medical Systems

Industry-Expert Theaters

Sunday, October 25

12:00 p.m. – 1:00 p.m. | AstraZeneca
Presentation Title: Treatment in Unresectable Stage III Non-Small Cell Lung Cancer   
Treatment for Unresectable Stage III NSCLC Following Concurrent Chemoradiation Therapy
    

Speaker: Alexander C. Whitley, MD, PhD, FACRO, Medical Director, Central Alabama Radiation Oncology, Montgomery, AL
 

Monday, October 26

11:00 a.m. – 12:00 p.m. | Brainlab    
Presentation Title: First Clinical Applications of Exactrac Dynamic

Radiosurgical Planning: Brain and Spine Disease Considerations
Speaker: Maximilian Niyazi, MD, LMU Hospital Munich, Germany

IGRS Experience: Intra-cranial Tumors and Spine Metastasis Setups
Speaker: Philipp Freislederer, MS, LMU Hospital Munich, Germany

Radiotherapy Planning: Breast Disease Considerations
Mark De Ridder, MD, PhD, UZ Brussel, Belgium

IGRT Experience: Free-Breathing and Manual Breath-hold Breast Setups
Thierry Gevaert, PhD, UZ Brussel, Belgium

11:00 a.m. – 12:00 p.m. | Bristol Myers Squibb    
Presentation Title: Investigating the Potential of Immuno-Oncology Research                                     

12:00 p.m. – 1:00 p.m. | CIVCO Radiotherapy
Presentation Title: Stereotactic Setups and Treatments: A Clinical Perspective    
This presentation examines the common challenges and important clinical considerations that must be met when performing patient setups for stereotactic treatments. Particular focus will be given to cranial SRS and SBRT, and the heightened setup demands that accompany these treatments.  Clinical guest speakers share their experiences of working with CIVCO positioning devices in the stereotactic environment, and tips and techniques for device and patient setup are demonstrated. Planning considerations are also addressed, and two studies that highlight the efficacy of a novel positioning device are discussed.

Speakers: Sean Santoscoy - RT(T) Product Specialist, CIVCO Radiotherapy
Bill Barnat, Product Specialist, Research and Development, CIVCO Radiotherapy
Chin Loon Ong Medical Physicist Haga Hospital, Netherlands
Luis Madureira, Clinical Education and Training Manager, Medical Physics, CIVCO Radiotherapy
Amanda Jasek - BSRT (R)(T) Clinical Applications Specialist, CIVCO Radiotherapy
Dawn DeBartolo, BSRT (T) Clinical Applications Specialist, CIVCO Radiotherapy
Ben Allen, Technical Lead Radiographer QEH, Birmingham     

12:00 p.m. – 1:00 p.m. | Novocure Inc.    
Presentation Title: Tumor Treating Fields: Translating Science into Practice

Objectives:
•    Provide an overview of the mechanism of action of Tumor Treating Fields (TTFields) and evidence for activity in tumor cells
•    Share clinical trial experience with TTFields supporting its application in glioblastoma and malignant pleural mesothelioma (MPM)

Speakers: Dr. Pavan Jhaveri, Smith Radiation Oncology, Baylor College of Medicine
Dr. Samir P. Kanani, George Washington University
 

Tuesday, October 27

11:00 a.m. – 12:00 p.m. | ViewRay, Inc.
Presentation Title: Maximizing Clinical Value of MRIdian – Dana-Farber/Brigham Women’s Cancer Center

12:00 p.m. – 1:00 p.m. | Janssen Biotech, Inc.    
Presentation Title: ERLEADA: TITAN and New Data for SPARTAN Final Analysis      

Speakers: Dr. Steven Finkelstein, Florida Cancer Affiliates (The US Oncology Network)
Dr. David Crawford, University of San Diego California

Wednesday, October 28

11:00 a.m. – 12:00 p.m. | Seattle Genetics    
Presentation Title: TUKYSA® (tucatinib): A Treatment Option for patients with HER2+ metastatic breast cancer (MBC)     

Speaker: Rebecca Lynn Moroose, MD    

11:00 a.m. - 12:00 p.m. | ASTRO Expert Theater
Presentation Title: Code Development and Valuation: What Radiation Oncology Industry Stakeholders Need to Know
Radiation Oncology is a dynamic and innovative field.  Industry stakeholders frequently come to ASTRO with questions regarding coding and valuation for new technologies and services.  This is an opportunity to hear from ASTRO’s experts about the process, what’s involved, and why collaboration is critical.
 
ASTRO Experts:
Amar Rewari, MD, MBA – Dr. Rewari serves as a member of ASTRO’s Code Development and Valuation Committee.  He is also ASTRO’s RUC Alternate Advisor.
 
Catheryn Yashar, MD – Dr. Yashar serves as a member of ASTRO’s Code Development and Valuation Committee.  She is also ASTRO’s CPT Alternate Advisor
 
Bryan Hull, Esq., MPH – Mr. Hull is ASTRO’s Assistant Director of Health Policy.  He serves as the staff liaison to the Code Development and Valuation Committee, as well as the key staff point person for ASTRO’s CPT and RUC activities.
 

Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium. The symposium constitutes the content and views of the provider and is not part of the official ASTRO Annual Meeting program.

Sunday, October 25

5:00 p.m. - 6:30 p.m. | Session Title: Optimizing Care in Lung Cancer: Current and Emerging Biomarkers for Immuno-Oncology

Joint Accreditation Statement:
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education:
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: 
This program is intended for radiologists, medical oncologists, and other healthcare providers who care for patients with lung cancer.

Learning Objectives: 
  • Upon completion of this activity, participants should be able to:
  • Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Consider patients for enrollment in clinical trials investigating novel therapeutic approaches, including neoadjuvant/adjuvant immunotherapy in lung cancer
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
 

Sunday, October 25

5:45 p.m. - 6:45 p.m. | Session Title: Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancers: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy

For more information and to register, please visit www.PeerView.com/RadOnc2020 

Accreditation: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute Inc. is accredited by the ACCME to provide continuing medical education for physicians.

CME Credits:
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience:
This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, surgical oncologists, and other clinicians involved in the management of interdisciplinary, multimodal management of patients with esophageal or gastroesophageal junction cancer. 

Learning Objectives:
  • Describe the mechanisms by which immunotherapies harness the immune system in the treatment of esophageal and gastroesophageal junction (GEJ) cancers and the rationale for using immune checkpoint inhibition as adjuvant therapy in locally advanced and earlier-stage disease
  • Evaluate the latest clinical trials and data related to the use of adjuvant immunotherapy in locally advanced and earlier stages of esophageal or GEJ cancer
  • Develop optimal multidisciplinary treatment plans for patients with locally advanced and earlier- stage esophageal or GEJ cancer, including clinical trial enrollment, based on the available evidence, patient- and disease-related factors, and expert recommendations
This activity is supported through an educational grant from Bristol Myers Squibb.
 

Tuesday, October 27

5:30 p.m. - 6:30 p.m. | Session Title: Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence, and Practical Aspects Across a Range of Solid Tumors

For more information and to register, please visit www.PeerView.com/RadOnc2020 

Accreditation: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

CME Credits:
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience:
This activity has been designed to meet the educational needs of radiation oncologists and other clinicians involved in the management of interdisciplinary, multimodal management of patients with solid tumors.

Learning Objectives:
  • Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy
  • Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM
  • Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings
  • Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials
This activity is supported by an educational grant from Novocure.

15-Minute Lunchtime Product Demonstrations

Sunday, October 25

Time Company Product Name
12:00 p.m. - 12:15 p.m. ViewRay, Inc. Innovation in Action: What’s next for MRIdian
12:15 p.m. - 12:30 p.m. Philips Healthcare Pinnacle Evolution

Monday, October 26

Time Company Product Name
11:00 a.m. - 11:15 a.m. Qfix Qfix Encompass™ 15-CHannel Head Coil on Siemens 3T MR Scanner
11:15 a.m. - 11:30 a.m. CIVCO Radiotherapy  
11:30 a.m. - 11:45 a.m. IBA (Ion Beam Applications)  
11:45 a.m. - 12:00 p.m. Sun Nuclear Corporation SunCHECK
12:00 p.m. - 12:15 p.m. Varian Medical Systems Ethos™ Therapy
12:15 p.m. - 12:30 p.m. Philips Healthcare IntelliSpace Radiation Oncology
12:30 p.m. - 12:45 p.m. IBA (Ion Beam Applications)  
12:45 p.m. - 1:00 p.m. Elekta The Power of Personalized: How Elekta is fighting cancer through new Digital Solutions

Tuesday, October 27

Time Company Product Name
11:00 a.m. - 11:15 a.m. Brainlab Brainlab Elements 3.0
11:30 a.m. - 11:45 a.m. ViewRay, Inc. Innovation in Action: Real-Time, On-Table Adaptive
11:45 a.m. - 12:00 p.m. Mevion Medical Systems MEVION S250i Proton Therapy System®️ with HYPERSCAN®️ Pencil Beam Scanning (PBS)
12:00 p.m. - 12:15 p.m. Elekta ProKnow
12:15 p.m. - 12:30 p.m. Varian Medical Systems IDENTIFY
12:30 p.m. - 12:45 p.m. Sun Nuclear Corporation MultiMet Winston-Lutz Cube

Wednesday, October 28

Time Company Product Name
11:00 a.m. - 11:15 a.m. Brainlab Brainlab Elements 3.0

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550
www.astro.org

TERMS OF USE & PRIVACY POLICY

Connect With Us: